Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
Author(s) -
Xiaogang Weng
Publication year - 2013
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s44162
Subject(s) - monoclonal antibody , apoptosis , liver cancer , cancer research , metastasis , in vivo , insulin like growth factor , cancer , cancer cell , growth factor , monoclonal , hepatocellular carcinoma , antibody , receptor , in vitro , chemistry , biology , medicine , immunology , biochemistry , microbiology and biotechnology
One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom